Diabetes, Nutrition, Obesity and Eating Disorders

Focusing on cardiovascular diseases, stroke, and peripheral artery disease associated with diabetes, this track includes discussion on pathogenesis, risk reduction strategies, and emerging therapies.

Focusing on therapeutic options beyond insulin, this session covers SGLT2 inhibitors, GLP-1 receptor agonists, amylin analogs, and novel drug candidates, including their mechanisms, efficacy, and safety profiles.

Presentations in this track will delve into autoimmune mechanisms affecting pancreatic beta cells, islet biology, and advances in preserving or restoring pancreatic function. Both human studies and animal models will be addressed.

This track investigates hormones like leptin, adiponectin, glucagon, and others, and their roles in glucose regulation and metabolic disease. Discussion will include hormonal dysregulation and therapeutic targeting in diabetes and obesity.

This session will explore genetic predispositions to diabetes, the role of molecular biomarkers in disease detection and prognosis, and global epidemiological trends. Focus areas include genome-wide association studies (GWAS), predictive modeling, and the impact of ethnicity and environment on diabetes prevalence.

Explore the current state and future of artificial pancreas systems combining CGMs, insulin pumps, and intelligent control software. Real-world data, clinical trials, and regulatory perspectives will be discussed.

Updates on next-generation insulin analogs, ultra-rapid formulations, and innovations in insulin delivery devices, including smart insulin pens and patch pumps.

This session focuses on the development, implementation, and performance of automated insulin delivery systems (closed-loop), along with advances in control algorithms that optimize glucose regulation.

Learn how AI and decision support tools are being integrated into clinical practice to assist with diagnosis, treatment recommendations, and real-time glucose management.

Exploring digital therapeutics, AI-powered health platforms, telemedicine innovations, and mobile applications for diabetes management. Emphasis on usability, data security, and patient empowerment.

This session highlights the brain’s role in metabolic regulation, insulin resistance, and energy balance. Discussion includes brain imaging studies, neuroinflammation, and central insulin action.

This track examines how aging and cellular senescence contribute to metabolic disorders. Topics include mitochondrial dysfunction, oxidative stress, and anti-aging therapies with potential for diabetes prevention.

This session highlights the brain’s role in metabolic regulation, insulin resistance, and energy balance. Discussion includes brain imaging studies, neuroinflammation, and central insulin action.

Sessions here will cover evidence-based dietary interventions, personalized nutrition plans, nutritional genomics, and the role of the Mediterranean, low-carb, and plant-based diets in managing diabetes and obesity.

This session addresses complications such as retinopathy, nephropathy, and neuropathy, discussing pathophysiology, early detection, and advanced management strategies to mitigate progression and improve outcomes.

Focusing on the biological and behavioral determinants of weight gain and maintenance, this session will explore neural, hormonal, and environmental influences on appetite, metabolism, and satiety.

Explore how digital tools, mobile health apps, wearables, and remote monitoring are transforming diabetes care. The session also examines healthcare access, policy, and equity implications of emerging technologies.

This timely track examines how the COVID-19 pandemic has impacted people with diabetes, including increased risks, complications, vaccine responses, and long-term metabolic consequences of the virus.